Drugs / Vancomycin
Vancomycin
DrugVancomycin is a glycopeptide antibacterial agent; in this oral Vancocin label it is indicated for Clostridioides difficile-associated diarrhea and staphylococcal enterocolitis, with explicit limitation that oral dosing is not effective for other infection types. U.S. initial approval in this oral capsule label is 1986.
- Trials
- 368
- Recruiting
- 39
- Completed
- 181
- With results
- 127
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 1 | — | — | 1 | 3 | 2 | 1 | — | — | — | 8 |
| Phase 1 | 5 | 1 | — | 1 | 15 | 1 | 2 | — | 4 | — | 29 |
| Phase 1/2 | 4 | — | — | — | 3 | 1 | — | — | 1 | — | 9 |
| Phase 2 | 7 | 5 | 1 | 4 | 33 | 15 | 1 | — | 6 | — | 72 |
| Phase 2/3 | 2 | — | — | — | 2 | 3 | 1 | — | 4 | — | 12 |
| Phase 3 | 6 | 2 | — | 1 | 46 | 10 | 3 | 1 | 3 | — | 72 |
| Phase 4 | 9 | 5 | 2 | — | 44 | 18 | 3 | — | 13 | — | 94 |
| Not applicable | 5 | 3 | — | — | 21 | 5 | 2 | — | 16 | — | 52 |
| Unknown | — | — | — | — | 14 | 1 | — | — | 4 | 1 | 20 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Clostridium Infections | — | 3 | 1 | 8 | 5 | 17 | 11 | 6 | — | 51 |
| Infections | 1 | 2 | — | 2 | — | 10 | 11 | 11 | 2 | 39 |
| Surgical Wound Infection | — | 1 | — | 1 | 1 | 6 | 11 | 5 | 2 | 27 |
| Staphylococcal Infections | — | — | — | 3 | — | 8 | 5 | 1 | 2 | 19 |
| Cellulitis | — | — | — | 2 | — | 12 | 3 | — | 1 | 18 |
| Bacteremia | — | — | — | 5 | 1 | 4 | 3 | — | 1 | 14 |
| Diarrhea | — | — | — | 3 | 1 | 7 | 3 | — | — | 14 |
| Bacterial Infections | — | 1 | — | 2 | — | 9 | — | — | 1 | 13 |
| Cholangitis, Sclerosing | 1 | 4 | — | 3 | 1 | 1 | 1 | 1 | 1 | 13 |
| Sepsis | — | 1 | — | 2 | — | 2 | 1 | 5 | 2 | 13 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 12 | 4 |
| 2 | Pfizer | 11 | 5 |
| 3 | Cumberland Pharmaceuticals | 8 | 5 |
| 4 | Mayo Clinic | 6 | 2 |
| 5 | Assiut University | 5 | 0 |
| 6 | Forest Laboratories | 5 | 2 |
| 7 | Melinta Therapeutics, Inc. | 5 | 4 |
| 8 | Actelion | 4 | 3 |
| 9 | Arizona State University | 4 | 0 |
| 10 | Hamilton Health Sciences Corporation | 4 | 1 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Vancomycin | 368 |
| 2 | Daptomycin | 39 |
| 3 | Linezolid | 31 |
| 4 | Cefazolin | 30 |
| 5 | Fecal Microbiota Transplantation | 23 |
| 6 | Metronidazole | 22 |
| 7 | Ciprofloxacin | 18 |
| 8 | Gentamicins | 17 |
| 9 | Fidaxomicin | 16 |
| 10 | Oxacillin | 16 |
Evidence
- Results reported
- 70.2%127 of 181 completed
- Published
- 16.6%30 of 181 completed
- Primary endpoint met
- 44.4%12 of 27 analyses
- Median months to report
- 15
Documents disclosed
Trial profile
- Median enrollment
- 80
- Median duration
- 27months
- Countries
- 66
- Study sites
- 2773
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 12
- Phase 1
- 25
- Phase 1/2
- 33
- Phase 2
- 66
- Phase 2/3
- 40
- Phase 3
- 350
- Phase 4
- 89
- Not applicable
- 65
- Unknown
- 165
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Houston | United States | 28 |
| 2 | Columbus | United States | 24 |
| 3 | Chicago | United States | 22 |
| 4 | Barcelona | Spain | 19 |
| 5 | Boston | United States | 19 |
| 6 | New York | United States | 18 |
| 7 | Baltimore | United States | 17 |
| 8 | Los Angeles | United States | 17 |
| 9 | Madrid | Spain | 17 |
| 10 | Minneapolis | United States | 17 |
Terminations
- Terminated
- 56
- Withdrawn
- 13
- Suspended
- 1
- Stopped for recruitment
- 5.7%21 of 368 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT07221708 Withdrawn | Withdrawn | Recruitment for end-points deemed not feasible. | 2027-12-31 |
| NCT04401553 Withdrawn | Withdrawn | The study never initiated. | 2026-08-31 |
| NCT05370885 Terminated | Terminated | Following review of Part 1 study data, the Sponsor decided to terminate the study with immediate effect. Results indicated that VE202 was not superior to placebo on the primary or any of the secondary endpoints. No new safety concerns were observed. | 2025-08-29 |
| NCT03723551 Terminated | Terminated | This trial was concluded for strategic reasons. | 2025-04-23 |
| NCT03710122 Terminated | Terminated | Funding terminated | 2025-03-20 |
| NCT02285140 Terminated | Terminated | Funding received for eventual full trial, and data rolled over into full trial. Full trial registered under NCT06567808. | 2025-03-10 |
| NCT05977868 Terminated | Terminated | DSMB recommendation based on safety benefit in Experimental (oral) arm | 2025-02-14 |
| NCT05077085 Withdrawn | Withdrawn | Withdrawn | 2024-12-31 |
| NCT05156437 Terminated | Terminated | The study was stopped because all five participants were lost to follow-up before completing treatment or any assessments, leaving no outcome data available and making continuation of the trial infeasible. | 2024-10-31 |
| NCT04246151 Withdrawn | Withdrawn | No patients enrolled. Identification of patients in allocated timeframe was not feasible. | 2024-09-12 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: